304 related articles for article (PubMed ID: 21556038)
1. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD
Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038
[TBL] [Abstract][Full Text] [Related]
2. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD
Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884
[TBL] [Abstract][Full Text] [Related]
4. In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment.
Rudolph G; Gotthardt DN; Kloeters-Plachky P; Kulaksiz H; Schirmacher P; Stiehl A
Dig Dis Sci; 2011 Dec; 56(12):3624-30. PubMed ID: 21656181
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis.
Ashraf I; Choudhary A; Arif M; Matteson ML; Hammad HT; Puli SR; Bechtold ML
Indian J Gastroenterol; 2012 Apr; 31(2):69-74. PubMed ID: 22528343
[TBL] [Abstract][Full Text] [Related]
6. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K
Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
[TBL] [Abstract][Full Text] [Related]
7. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
[TBL] [Abstract][Full Text] [Related]
9. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Tung BY; Emond MJ; Haggitt RC; Bronner MP; Kimmey MB; Kowdley KV; Brentnall TA
Ann Intern Med; 2001 Jan; 134(2):89-95. PubMed ID: 11177311
[TBL] [Abstract][Full Text] [Related]
10. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
[TBL] [Abstract][Full Text] [Related]
11. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis.
Singh S; Khanna S; Pardi DS; Loftus EV; Talwalkar JA
Inflamm Bowel Dis; 2013 Jul; 19(8):1631-8. PubMed ID: 23665966
[TBL] [Abstract][Full Text] [Related]
12. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
[TBL] [Abstract][Full Text] [Related]
13. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study.
Jørgensen KK; Lindström L; Cvancarova M; Castedal M; Friman S; Schrumpf E; Foss A; Isoniemi H; Nordin A; Holte K; Rasmussen A; Bergquist A; Vatn MH; Boberg KM
Scand J Gastroenterol; 2012 Sep; 47(8-9):1021-9. PubMed ID: 22577871
[TBL] [Abstract][Full Text] [Related]
14. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
Imam MH; Sinakos E; Gossard AA; Kowdley KV; Luketic VA; Edwyn Harrison M; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; DeCook AC; Enders F; Lindor KD
Aliment Pharmacol Ther; 2011 Nov; 34(10):1185-92. PubMed ID: 21957881
[TBL] [Abstract][Full Text] [Related]
15. Duration and severity of primary sclerosing cholangitis is not associated with risk of neoplastic changes in the colon in patients with ulcerative colitis.
Navaneethan U; Kochhar G; Venkatesh PG; Lewis B; Lashner BA; Remzi FH; Shen B; Kiran RP
Gastrointest Endosc; 2012 May; 75(5):1045-1054.e1. PubMed ID: 22405258
[TBL] [Abstract][Full Text] [Related]
16. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.
Broomé U; Löfberg R; Veress B; Eriksson LS
Hepatology; 1995 Nov; 22(5):1404-8. PubMed ID: 7590655
[TBL] [Abstract][Full Text] [Related]
17. Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis.
Stokkeland K; Höijer J; Bottai M; Söderberg-Löfdal K; Bergquist A
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1860-1866.e1. PubMed ID: 30448601
[TBL] [Abstract][Full Text] [Related]
18. The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation.
Eaton JE; Smyrk TC; Imam M; Pardi DS; Loftus EV; Owens VL; Talwalkar JA
Aliment Pharmacol Ther; 2013 Oct; 38(8):977-87. PubMed ID: 24033551
[TBL] [Abstract][Full Text] [Related]
19. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study.
Lindberg BU; Broomé U; Persson B
Dis Colon Rectum; 2001 Jan; 44(1):77-85. PubMed ID: 11805567
[TBL] [Abstract][Full Text] [Related]
20. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
